INforMD - Phase 3 Foslevodopa-Fascarbidopa - AbbVie

This article provides a comprehensive report on the Phase 3 trials of subcutaneous foslevodopa-fascarbidopa currently under development through AbbVie. The promising results suggest there to be an increase in on time without dyskensia and likewise a decrease in off time, as well as improved sleep.

Have an article you would like added or a category you would like to see, please send us an email.